ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MD vs ABBV // EV/EBITDA & P/E VALUATION

Pediatrix Medical Group Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: MD 5 — ABBV 3
▲ EV/EBITDA & P/E VALUATION LEADER: MD
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MD VS. ABBV) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MD ABBV SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 70.20% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 33.60% 29.00% +4.60 MD /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 9.6x 33.3x -23.70 MD /valuation <GO>
Free Cash Flow Yield 11.43% 3.47% +7.96 MD /fcf-yield <GO>
Operating Margin — 24.60% — TIE /operating-margins <GO>
Net Profit Margin — 6.90% — TIE /net-margins <GO>
Revenue Growth (YoY) — 8.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.27% -2.27 ABBV /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.33 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 7/9 -1.00 ABBV /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 71.7 65.1 +6.57 MD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.15 — TIE /macro-sensitivity <GO>
Forward P/E Multiple 13.3x 113.1x -99.80 MD /forward-pe <GO>
Enterprise Scale & Market Cap $2.37B $513.86B -$511.49B ABBV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MD REV ABBV REV MD GROSS % ABBV GROSS % MD FCF ABBV FCF
FY 2025 $0 $61.16B — 70.2% $271.1M $17.82B
FY 2024 $0 $56.33B — 70.0% $206.6M $17.83B
FY 2023 $0 $54.32B — — $137.3M $20.39B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MD // BETA —
ABBV // BETA 1.15